4-Chloro-6-Iodoquinazoline CAS 98556-31-1 Purity >98.0% (HPLC)

4-Chloro-6-Iodoquinazoline (CAS: 98556-31-1) is an intermediate in the synthesis of Lapatinib (CAS: 231277-92-2) / Lapatinib Ditosylate Monohydrate (CAS: 388082-78-8).
Lapatinib is a new breast cancer targeted therapy drug developed and manufactured by GlaxoSmithKline, which was approved by the U.S. Food and Drug Administration on March 13, 2007. The currently approved indication is combined with capecitabine for advanced or metastatic breast cancer, and breast cancer patients must be treated with other first-line drugs. Its trade name in the United States is Tykerb. On December 14, 2007, the European Medicines Agency (EMEA) approved the listing of Lapatinib in Europe under the trade name Tyverb. Molecular targeted therapy for breast cancer refers to the treatment of oncogenes and related expression products related to the occurrence and development of breast cancer. Molecular targeted drugs inhibit or kill tumor cells by blocking signal transduction in tumor cells or related cells to control changes in cell gene expression. Lapatinib is an oral small molecule epidermal growth factor tyrosine kinase inhibitor. Clinical trials have shown that for HER2 breast cancer patients who have developed resistance to Roche's Herceptin (Herceptin), Lapatinib has a good clinical effect. In vitro tests, Lapatinib had a significant growth inhibitory effect on Her-2 overexpressing breast cancer cell lines. In Phase I trials of advanced breast cancer with Her-2 overexpression, Lapatinib also has a high effective rate and has no cross-resistance to Herceptin (trastuzumab). Because its structure is a small molecule, unlike Herceptin (trastuzumab), it can penetrate the blood-brain barrier and has a certain therapeutic effect on brain metastasis of breast cancer.